Sept 2018 | Targeted Therapies in Oncology

September 28, 2018

Antibody–drug conjugate therapies are making a larger impact on the treatment paradigm for patients with lymphomas, especially following promising data for brentuximab vedotin and inotuzumab ozogamicin.

September 25, 2018

Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, for patients with relapsed/refractory multiple myeloma, as well as emerging immunotherapy treatment options.

September 22, 2018

Patients with the localized form of CRPC still have no options that are proven to extend overall survival, but preliminary results from the PROSPER trial of enzalutamide and the SPARTAN trial of apalutamide offer them unprecedented hope.

September 21, 2018

Combinations of novel drugs used for treating patients with lymphomas may have the potential to improve responses and overcome resistance to therapy but can be accompanied by unexpected adverse events that demand careful monitoring, Kieron Dunleavy, MD, cautioned during the 2018 Pan Pacific Lymphoma Conference.

September 20, 2018

HER2 mutations have been identified as another oncogenic driver in the growing list of actionable targets in non–small cell lung cancer. Based on a mounting body of evidence on the impact of HER2 mutations in lung cancer and the growing focus on personalized medicine, the HER2 receptor has gained focus as a potential target for precision medicine treatments for patients with NSCLC.

September 20, 2018

Medicare patients could save an estimated $150 million on out-of-pocket co-payments for clinic visits if proposed changes to the hospital Outpatient Prospective Payment System and Ambulatory Surgical Cancer payment system are adopted by the Centers for Medicare & Medicaid Services for 2019.

September 20, 2018

Increased focus has been placed on the overwhelming stress within the physician community, often referred to as burnout. According to Medscape’s 2018 National Physician Burnout and Depression Report, nearly twothirds of physicians within the United States have reported symptoms.

September 19, 2018

Only 1 treatment option is currently available for treating patients with metastatic germline BRCA-mutated triple-negative breast cancer, but research into novel therapies, including PI3K/conjugates could soon result in a host of new therapies for this hard-to-treat disease.

September 19, 2018

Quick progress was seen with a novel class of agents, chimeric antigen receptor T-cell therapies, in the setting of diffuse large B-cell lymphoma—a swift jump from early phase clinical trials to FDA-approved products.

September 19, 2018

Adding selective internal radiation therapy to chemotherapy improved overall survival by 5 months compared with chemotherapy alone for patients with liver-only or liver-dominant right-sided primary metastatic colorectal cancer, according to results from a post hoc analysis of 2 randomized, controlled trials.

September 18, 2018

Despite progress seen with immune checkpoint inhibitors in Hodgkin lymphoma, there remains an unmet need for greater responses, which could be filled by potential combination approaches, according to Stephen M. Ansell, MD, PhD.

September 18, 2018

Two oncologists from the Winship Cancer Institute of Emory University reviewed data for and against the use of chemotherapy for patients with resectable colorectal cancer liver metastases. Mehmet Akce, MD, spoke in favor of chemotherapy, while Shishir K. Maithel, MD, argued against it.

September 17, 2018

Long-term metastatic control is an important goal for patients with high-risk renal cell carcinoma after nephrectomy. In recent years, adjuvant therapy with tyrosine kinase inhibitors has entered the picture to potentially fill this unmet need.